Innovations In Clinical Neuroscience

HOTTOP Multiple Sclerosis MAR 2018

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link:

Contents of this Issue


Page 20 of 23

R E V I E W 21 Hot Topics in Multiple Sclerosis [March 2018] 2009;374:1503–11. 90. Arnold DL, Narayanan S, Antel S. Neuroprotection with glatiramer acetate: evidence from the PreCISe trial. J Neurol. 2013;260:1901–6. 91. Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler. 2013;19:1074–83. 92. Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain. 2001;124(Pt 9):1803–12. 93. Sormani MP, Rovaris M, Valsasina P, et al. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology. 2004;62(8):1432–4. 94. Khan O, Rieckmann P, Boyko A, et al. Efficacy and safety of a three-times- weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open- label extension study. Mult Scler. 2016;23:818–29. 95. Fisher E, Nakamura K, Lee JC, et al. Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: a retrospective analysis. Mult Scler. 2016;22:668–76. 96. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. CARE-MS I. Lancet. 2012;380:1819–28. 97. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. CARE-MS II. Lancet. 2012;380:1829–39. 98. Rinaldi F, Perini P, Atzori M, et al. Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing- remitting multiple sclerosis: results from a 48-month extension study. Mult Scler Int. 2015;2015:369348. 99. Dwyer MG, Zivadinov R, Tao Y, et al. Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open- label two-arm trial. BMC Neurol. 2015;15:232. 100. Seppi D, Polo D, Rinaldi F, et al. Effect of natalizumab on global and regional cortical thickness in RRMS: a four year longitudinal study highlights efficacy and stresses the importance of a well- timed intervention. Mult Scler J. 2016;22(S3):605. 101. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing MS multiple sclerosis. N Engl J Med. 2011;365:1293–303. 102. Radue E, Sprenger T, Gaetano L, et al. Teriflunomide slows down brain volume loss in relapsing MS: a SIENA analysis of the TEMSO MRI dataset. Presented at: 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Barcelona, Spain, 7–10 October 2015. 103. Miller DH, Fox RJ, Phillips JT, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study. Neurology. 2015;84:1145–52. 104. Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 DEFINE study. J Neurol. 2014;261:1794–802. 105. Dupuy SL, Tauhid S, Hurwitz S, et al. The effect of dimethyl fumarate on cerebral gray matter atrophy in multiple sclerosis. Neurol Ther. 2016;5:215–29. 106. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. FREEDOMS study group. N Engl J Med. 2010;362:387–401. 107. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo- controlled, phase 3 trial. Lancet Neurol. 2014;13:545–56. 108. De Stefano N, Tomic D, Radue EW, et al. Effect of fingolimod on diffuse brain tissue damage in relapsing- remitting multiple sclerosis patients. Mult Scler Relat Disord. 2016;7:98– 101. 109. Radue EW, Barkhof F, Kappos L, et al. Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Neurology. 2015;84:784–93. 110. Sastre-Garriga J, Tur C, Pareto D, et al. Brain atrophy in natalizumab- treated patients: a 3-year follow-up. Mult Scler. 2015;21:749–56. 111. Magraner M, Coret F, Casanova B. The relationship between inflammatory activity and brain atrophy in natalizumab treated patients. Eur J Radiol. 2012;81:3485–90. 112. Mellergård J, Tisell A, Blystad I, et al. Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis. Eur J Neurol. 2017;24:112–21. 113. Traboulsee A, Pelletier D, Comi G, et al. Alemtuzumab reduces the rate of brain volume loss in RRMS patients who switched from SC IFNB-1a to alemtuzumab (4-year-follow-up of the CARE-MS I and II studies). Mult Scler J. 2016;22(S3):613. 114. Borges IT, Shea CD, Ohayon J, et al. The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2013;2:133–40. 115. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376:209–20. 116. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta- 1a in relapsing multiple sclerosis. New Engl J Med. 2017;376:221–34. 117. Giovannoni G, Comi G, Cook S, et al. A placebo controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26. 118. De Stefano N, Giorgio A, Battaglini M, et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing remitting multiple sclerosis treated with cladribine tablets. Mult Scler. 2017;2017:1–5. MS

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - HOTTOP Multiple Sclerosis MAR 2018